Latest news
Genentech's Chief Diversity Officer Quita Highsmith points out that there are multiple myths about clinical trial diversity and introduces how the company, through studies like Chimes, has proven that engaging diverse patients does not compromise scientific rigor.
Dr. Julie Gerberding, CEO of the Foundation for the National Institutes of Health and former CDC Director, shares insights in an exclusive interview on R&D hotspots such as cancer immunotherapy, women's health, ALS, preeclampsia, and mental health, as well as topics including rebuilding public health trust and PAHPA reauthorization.
Adam Lenkowsky, who has spent over 26 years at Bristol Myers Squibb, rose from a sales representative to Chief Commercial Officer. He has witnessed multiple strategic shifts as the company transitioned from a diversified conglomerate to a pure biopharmaceutical firm, and has observed profound changes in industry innovation speed, market access policies, and digital marketing. In light of the portfolio expansion from the Mirati acquisition, he outlines the evolution of future commercialization models and his predictions regarding the impact of the Inflation Reduction Act in 2024.
Janet Dorling, Senior Vice President at Gilead Sciences, visited nine countries within her first 90 days on the job, engaging with local healthcare providers and community members, and gaining a deep appreciation for the daily dangers HIV advocates face in some countries. She emphasizes advancing global health equity through purposeful partnerships and reveals that the company is exploring long-acting HIV treatments while still in the building phase in oncology.
Cristina Durán, President of AstraZeneca's digital health company Evinova, gave an exclusive interview exploring the value of data in drug development. She noted that technologies such as telemedicine and home monitoring help detect diseases earlier, and shared strategies for platform-based solutions across therapeutic areas, as well as a cautious approach to emerging technologies like AI.
Dr. Juan Camilo Arjona Ferreira, Chief Medical Officer at Organon, joined the company in September 2023, committed to advancing women's health with a fresh perspective. He proposes a three-dimensional matrix strategy that views the female life cycle as a continuum, emphasizing scientific leadership and inclusive research, while also focusing on 2024 pipeline progress and policy opportunities.
AstraZeneca released a report indicating that among immunocompromised populations (such as cancer patients and organ transplant recipients), over 10% still fail to produce protective antibodies even after multiple vaccinations. Its two real-world studies, covering millions of health records in the UK and the US, found that immunocompromised individuals accounted for 22% of COVID-19 hospitalizations, 28% of ICU admissions, and 24% of deaths in 2022. Based on an interview with Professor Paul Moss from the University of Birmingham, UK, this article explores preventive antibody therapies, individualized risk assessment, and future policy directions.
Wisp interim CEO Monica Cepak speaks with PharmaVoice, sharing how the company challenges double standards in women's health topics with bold advertising strategies, and introduces its telehealth service expansion plans and 90-day work priorities.
After a brief retirement, Dr. Mark Goldberg returned to the industry and now leads the CRO company Allucent. He reflects on his 21 years at Parexel, early medical imaging applications, and discusses technology trends in clinical trials, including decentralized trials and AI applications.